Accounts Receivable
The latest quarterly a/r is $544.70 Million with a quarter-over-quarter change of +5.38%. Accounts Receivable (A/R) represents money owed to the company by customers for goods or services delivered but not yet paid for.
PODD A/R
Reported quarterly accounts receivable; no daily interpolation.
Current A/R
$544.70M
$544.70 Million
Quarter-over-Quarter Change
+5.38%
vs. $516.90M prior quarter
Historical Data
80
Quarters of data available
Quarterly A/R History
| Period | A/R | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $544.70M | +$27.80M | +5.38% |
| Q4 2025 | $516.90M | +$54.70M | +11.83% |
| Q3 2025 | $462.20M | +$17.70M | +3.98% |
| Q2 2025 | $444.50M | +$42.20M | +10.49% |
| Q1 2025 | $402.30M | +$36.80M | +10.07% |
| Q4 2024 | $365.50M | $-10.10M | -2.69% |
| Q3 2024 | $375.60M | +$27.00M | +7.75% |
| Q2 2024 | $348.60M | +$28.10M | +8.77% |
| Q1 2024 | $320.50M | $-39.20M | -10.90% |
| Q4 2023 | $359.70M | +$89.40M | +33.07% |
| Q3 2023 | $270.30M | +$19.80M | +7.90% |
| Q2 2023 | $250.50M | +$33.30M | +15.33% |
| Q1 2023 | $217.20M | +$11.60M | +5.64% |
| Q4 2022 | $205.60M | +$4.20M | +2.09% |
| Q3 2022 | $201.40M | $-5.20M | -2.52% |
| Q2 2022 | $206.60M | +$17.30M | +9.14% |
| Q1 2022 | $189.30M | +$28.30M | +17.58% |
| Q4 2021 | $161.00M | +$46.70M | +40.86% |
| Q3 2021 | $114.30M | +$14.00M | +13.96% |
| Q2 2021 | $100.30M | +$2.40M | +2.45% |
| Q1 2021 | $97.90M | +$14.10M | +16.83% |
| Q4 2020 | $83.80M | $-1.60M | -1.87% |
| Q3 2020 | $85.40M | +$7.40M | +9.49% |
| Q2 2020 | $78.00M | $-2.10M | -2.62% |
| Q1 2020 | $80.10M | $-2.70M | -3.26% |
| Q4 2019 | $82.80M | +$5.26M | +6.79% |
| Q3 2019 | $77.54M | $-1.20M | -1.53% |
| Q2 2019 | $78.74M | +$581,000 | +0.74% |
| Q1 2019 | $78.16M | +$1.49M | +1.94% |
| Q4 2018 | $76.67M | $-3.24M | -4.06% |
| Q3 2018 | $79.91M | +$16.28M | +25.58% |
| Q2 2018 | $63.63M | +$7.80M | +13.98% |
| Q1 2018 | $55.83M | +$2.46M | +4.60% |
| Q4 2017 | $53.37M | +$6.20M | +13.14% |
| Q3 2017 | $47.17M | +$9.42M | +24.95% |
| Q2 2017 | $37.75M | $-2.90M | -7.12% |
| Q1 2017 | $40.65M | +$11.85M | +41.12% |
| Q4 2016 | $28.80M | $-9.74M | -25.28% |
| Q3 2016 | $38.55M | $-152,000 | -0.39% |
| Q2 2016 | $38.70M | $-1.77M | -4.38% |
| Q1 2016 | $40.47M | $-2.06M | -4.83% |
| Q4 2015 | $42.53M | +$10.73M | +33.73% |
| Q3 2015 | $31.80M | $-23,000 | -0.07% |
| Q2 2015 | $31.83M | $-4.27M | -11.82% |
| Q1 2015 | $36.09M | $-3.79M | -9.50% |
| Q4 2014 | $39.88M | $-7.26M | -15.41% |
| Q3 2014 | $47.15M | +$5.35M | +12.80% |
| Q2 2014 | $41.80M | +$5.12M | +13.95% |
| Q1 2014 | $36.68M | +$3.61M | +10.92% |
| Q4 2013 | $33.07M | $-1.40M | -4.06% |
| Q3 2013 | $34.47M | +$815,000 | +2.42% |
| Q2 2013 | $33.65M | +$2.54M | +8.16% |
| Q1 2013 | $31.11M | $-2.18M | -6.56% |
| Q4 2012 | $33.29M | +$3.15M | +10.45% |
| Q3 2012 | $30.14M | +$4.55M | +17.80% |
| Q2 2012 | $25.59M | $-606,000 | -2.31% |
| Q1 2012 | $26.20M | +$3.01M | +12.97% |
| Q4 2011 | $23.19M | +$5.92M | +34.29% |
| Q3 2011 | $17.27M | $-3.09M | -15.19% |
| Q2 2011 | $20.36M | +$5.35M | +35.66% |
| Q1 2011 | $15.01M | $-1.83M | -10.88% |
| Q4 2010 | $16.84M | +$1.40M | +9.06% |
| Q3 2010 | $15.44M | $-359,000 | -2.27% |
| Q2 2010 | $15.80M | +$595,000 | +3.91% |
| Q1 2010 | $15.21M | +$244,000 | +1.63% |
| Q4 2009 | $14.96M | $-1.40M | -8.53% |
| Q3 2009 | $16.36M | +$848,000 | +5.47% |
| Q2 2009 | $15.51M | +$2.22M | +16.69% |
| Q1 2009 | $13.29M | +$281,000 | +2.16% |
| Q4 2008 | $13.01M | +$1.17M | +9.86% |
| Q3 2008 | $11.84M | +$2.08M | +21.33% |
| Q2 2008 | $9.76M | +$2.54M | +35.12% |
| Q1 2008 | $7.22M | +$2.44M | +51.01% |
| Q4 2007 | $4.78M | +$1.44M | +43.08% |
| Q3 2007 | $3.34M | +$710,000 | +26.97% |
| Q2 2007 | $2.63M | +$515,000 | +24.32% |
| Q1 2007 | $2.12M | +$701,000 | +49.47% |
| Q4 2006 | $1.42M | +$415,000 | +41.42% |
| Q3 2006 | $1.00M | +$862,000 | +615.71% |
| Q4 2005 | $140,000 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy